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Summary The nuclear DNA content of 351 breast carcinomas was determined by flow cytometry from
paraffin-embedded tissue to assess the prognostic significance of DNA ploidy, the DNA index (DI) and the
S-phase fraction (SPF). The minimum follow-up ofthe patients was 22 years, and they were all from a defined
urban population. DNA ploidy correlated with histological type and grade, mitotic count and nuclear
pleomorphism (P<0.0001), and also with axillary nodal status (P=0.0005), tumour necrosis (P=0.001),
primary tumour size (P = 0.03), menopausal status (P = 0.004) and the presence of distant metastases at the
time of the diagnosis (P = 0.04). Survival corrected for intercurrent deaths of the patients with a diploid
tumour was better than that of the patients with a non-diploid tumour (P = 0.0001, 48% vs 28% at 25 years).
SPF had prognostic significance in both axillary node positive and negative patients, but ploidy and DI only
in the node negative group, and their significance was greater in post-menopausal than in premenopausal
patients. Axillary nodal status, primary tumour size, histological grade and the type of tumour margin
circumscription were the most important independent prognostic factors in Cox's multivariate analysis, and
SPF had independent prognostic value, whereas ploidy and DI did not. It is concluded that DNA ploidy, DI
and SPF have long-term prognostic significance in breast cancer.
The need of reliable prognostic factors in breast cancer has
increased, since recent advances in treatment, such as ad-
juvant hormonal and chemotherapy, require their careful
assessment. Breast cancer is biologically a heterogeneous
disease, and the prediction of its clinical outcome is difficult
in individual cases. A number of factors, such as the clinical
stage, nodal status, primary tumour size, histological type,
histological and cytological grade of differentiation, mitotic
count or index, steroid receptor content, presence of tumour
necrosis, immunohistochemical staining properties and ampli-
fication of oncogenes have been found to be of prognostic
value (Fisher et al., 1984; Baak et al., 1985; Shek & Godol-
phin, 1988; Kuhajda & Eggleston, 1985; Leatham & Brooks,
1987; Slamon et al., 1987).
The nuclear DNA content determined by flow cytometry
has recently emerged as a new prognostic factor in breast
cancer. The technique has gained some popularity, since flow
cytometric histograms are rapid to produce and often easy to
interpret. It has been suggested that breast carcinomas with
an abnormal (non-diploid or aneuploid) nuclear DNA con-
tent are associated with less favourable prognosis than
carcinomas with a normal (diploid) DNA content (Hedley et
al., 1984, 1987; Coulson et al., 1984; Ewers et al., 1984;
Thorud et al., 1986; Baildam et al., 1987; Cornelisse et al.,
1987; Kallioniemi et al., 1987; Stal et al., 1989). Similarly, the
DNA index (DI, the relative DNA content of an aneuploid
stemline of cells as compared with diploid cells) and the
percentage of S-phase cells in the DNA histogram (S-phase
fraction, SPF) have been found by some to be of prognostic
significance (Dowle et al., 1987; Hedley et al., 1987; Kal-
lioniemi et al., 1988; Stal et al., 1989; McDivitt et al., 1986;
Klintenberg et al., 1986). However, the prognostic value of
nuclear DNA content analysis is still unsettled. Some authors
report DNA content to be the most important prognostic
variable in breast cancer, and to have independent prognostic
value in a multivariate analysis (Kallioniemi et al., 1988),
whereas others find it to have prognostic value only in a
univariate analysis (Stal et al., 1989; Hedley et al., 1984), and
yet a few fail to find any prognostic significance at all when
overall survival is concerned (van der Linden et al., 1989;
Uyterlinde et al., 1988; Owainati et al., 1987). The series
published have often been heterogeneous, comparison of
ploidy with other prognostic variables selective and inade-
quate, and the follow-up times short.
The purpose of the present study was to investigate the
significance of DNA ploidy, DI and SPF on the long-term
prognosis of breast cancer in a defined urban population,
and their correlation to a number of suggested
clinicopathological prognostic variables.
Materials and methods
Patients
Four hundred and sixty-one cases of histologically verified
female breast carcinoma were diagnosed in the city of Turku
in South-Western Finland from 1945 to 1965 according to
hospital records and data from the Finnish Cancer Registry.
During these years the female population increased from
48,100 to 74,800. The age-adjusted incidence figures for
breast cancer are available since 1953, and from the 5-year
period 1953-57 to 1963-67 the incidence increased from
30.8 to 41.6 per 100,000 women. The great majority of the
patients were treated at the University Central Hospital of
Turku, and the rest at the City Hospitals. Seven patients
were treated elsewhere, and five were lost from follow-up,
and these cases were excluded from the study.
Paraffin blocks for DNA content determination were avail-
able in 430 cases with complete follow-up data, and in 384
cases (89%) an interpretable DNA histogram was obtained.
Thirty-three of the 384 patients were excluded, because 20
patients developed a second primary carcinoma in the re-
maining breast, and 13 had either intraductal in situ car-
cinoma or Paget's disease, leaving 351 patients with invasive
carcinoma in the series. Two patients who died within 1
month from the diagnosis were not included in the survival
analyses (n = 349).
The clinical data and cause of death were obtained from
the hospital records, which were reviewed, and from the files
of the Finnish Cancer Registry, the Central Statistical Office
of Finland, and from local authorities. All autopsy protocols
and histological sections were reviewed. The mean and
median age at diagnosis were 56 years (range 30-89 years),
and patients older than 49 years were considered as post-
menopausal. The mean follow-up time was 28 years (median,
27 years, range 22-42 years). Thirty-five (10%) of the
patients had stage I, 190 (54%) stage II, 103 (29%) stage III,
and 23 (7%) stage IV cancer according to the UICC post-
surgical TNM classification. Thirteen patients had inflam-
matory and 16 ulcerative cancer. Two-hundred and three
(58%) patients were treated with radical mastectomy, 75 with
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mastectomy and axillary evacuation, 54 with simple mastec-
tomy, 15 with simple excision and four had biopsy only.
Postopreative radiotherapy was given to 243 (69%) patients.
Histology
New Haematoxylin & Eosin and van Gieson stained slides
were prepared, and the original van Gieson stained slides
were reviewed in each case. All available biopsy material
before and after cancer diagnosis was reviewed. The his-
tological grading and typing of the tumours was done, slight-
ly modifying the WHO classification. The tumours were
subsequently grouped in univariate and multivariate analyses
into three types; (1) infiltrating ductogenic carcinoma not
otherwise specified (NOS, includes also apocrine, mixed muc-
inous, and atypical medullary types); (2) infiltrating lobular
carcinoma (includes variants); and (3) other special types
(includes tubular, medullary, cribriform, papillary, metaplas-
tic and pure mucinous carcinomas). Several other histopath-
ological features, including the number of mitoses per high
power field, tubule formation, nuclear pleomorphism, extent
of tumour necrosis, amount of stromal fibrosis and elastin,
inflammatory cell reaction in and around the tumour, type of
tumour margin circumscription (definite margin vs diffuse
growth pattern) and extent of intraductal growth were eval-
uated semiquantitatively.
DNA flow cytometry
Paraffin-embedded biopsies were processed for flow cyto-
metry by the method of Hedley et al. (1983) with slight
modifications. Two 50ltm sections were cut, and one or
more adjacent 5 iim control sections were cut for light mic-
roscopy. DNA was stained with propidium iodide (Vindel0v
et al., 1983), and flow cytometry was done with a FacStar
flow cytometer (Becton-Dickinson Immunocytometry Sys-
tems, Mountain View, CA). A 488 nm argon laser line run at
600 mW was used for fluorescence excitation. A 585 ± 42 nm
band-pass filter was used in front of the red photomultiplier
to block the laser light. For each histogram 20,000 particles
were analysed.
DNA ploidy was independently assessed by two of the
authors without any knowledge of the clinicopathological or
survival data. Histograms with a symmetrical GO/GI peak
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were classified as diploid, and those with an asymmetrical
GO/GI peak (with a 'shoulder') as near-diploid. Because
there was no difference in survival between patients with a
diploid or near-diploid tumour, they were combined in statis-
tical analyses and formed the 'diploid' subgroup. If two
GO/GI peaks were present, the histogram was classified as
aneuploid and, if more than two, as multiploid. A histogram
with a GO/GI peak at 4N and a G2/M peak at 8N was
classified as tretraploid. Because there was no difference in
survival between patients with aneuploid, tetraploid or mul-
tiploid cancer, there were combined in statistical analyses and
formed the 'non-diploid' subgroup. Examples of different
types of DNA histograms are given in Figure 1. The DNA
index (DI) was calculated by dividing the modal channel
number of an aneuploid peak by the modal channel number
of the diploid peak. The peak with the least DNA content
was taken as the diploid peak. The coefficient of variation
(CV) ranged from 2.6 to 9.8. Diploid tumours with CV over
10% and those with excessive cell debris were not included in
the study. The S-phase fraction (SPF) was calculated accord-
ing to the rectilinear method of Baisch et al. (1975). SPF
could be calculated in 223 (64%) cases. It was not calculated
if the height of the S-phase could not be reliably assessed
because of overlapping stemlines or the presence of cell
debris. The height of SPF was measured near the G2/M peak
to avoid counting cell debris. In aneuploid cases with a large
DI (> 1.3), SPF was calculated for the aneuploid stemline
only.
Statistical methods
Frequency tables were analysed with the X2 test. Comparison
of age at the diagnosis and SPF in different ploidy groups
was done with Kruskal-Wallis' analysis of variance and
Mann-Whitney's U test because of the markedly non-normal
distributions. The survival analysis was performed with the
BMDP computer program (BMDP Statistical Software,
Department of Biomathematics, University of California, Los
Angeles, CA). The cumulative survival was estimated with
the product-limit method, and comparison of survival
between groups was' calculated by Wilcoxon-Breslow and
Mantel-Cox statistics. Both crude survival and survival cor-
rected for intercurrent deaths were calculated. The relative
importance of prognostic factors was assessed with Cox's
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Figure 1 Examples of DNA flow cytometric histograms. a, A diploid histogram with one roughly symmetric GI peak. SPF 4.1%
b, A near diploid histogram with an asymmetric GI peak. SPF 3.7%. c, An aneuploid histogram with two GI peaks. DI 1.73,
SPF 16.1%. d, An aneuploid histogram with DI 1.19, SPF 6.1%. e, A tetraploid histogram with a tetraploid peak on the channel
118, and the diploid peak on channel 60. SPF 23.7%. f, A multiploid histogram with two aneuploid peaks (DI 1.67 and 1.88).
d = diploid stemline, a = aneuploid stemline, t = tetraploid stemline, s = S-phase fraction.
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proportional hazard model (BMDP 2L). All P values are
two-tailed.
Results
DNA ploidy
One hundred and eleven (32%) of the cancers were diploid
(74 had a symmetrical and 37 as asymmetrical GI peaks),
and 240 (68%) non-diploid (157 were aneuploid, 27 tetra-
ploid and 56 multiploid). The distribution of DNA indices is
shown in Figure 2. The distribution is bimodal with peaks in
the diploid/near diploid region, and in the hypertriploid/
tetraploid region. SPF ranged from 2.0 to 38.0%, median
9.0% (mean 11.6%, s.d. 7.9%).
Survival
The crude survival of all patients was 34% 10 years and 17%
25 years after the diagnosis, and the corresponding figures
corrected for intercurrent deaths were 41% and 34%. Cor-
rected survival of patients with diploid carcinoma was more
favourable than that of the patients with non-diploid cancer
(P = 0.0001). The 10-year survival of the patients with dip-
loid cancer was 53%, and the 25-year survival 48%, whereas
the corresponding figures for non-diploid cancer were 36%
and 28% (Figure 3). There was no significant difference in
survival between patients with aneuploid, tetraploid, or mul-
tiploid cancer.
After a series of calculations, the DI value 1.3 was found
to have most prognostic significance as a cut-off value. Car-
cinomas with DI < 1.3 had more favourable prognosis than
those with DI> 1.3 (P<0.0001, Figure 3). Carcinomas with
>7% S-phase cells were associated with inferior survival as
compared with those with SPF <7% (P<0.0001 (Figure 4);
the cut-off point was found by serial calculations with
different SPF values). If the cases in which SPF was cal-
culated for the aneuploid stemline only were considered
(DI> 1.3, n = 98), carcinomas with SPF> 13% had inferior
prognosis (P = 0.04), and if the rest of the cases were
analysed (DI < 1.3, n = 124), the best cut-off value was again
7% (P = 0.0007).
The prognostic influence of ploidy, DI and SPF after
stratification according to the menopausal or axillary nodal
status is shown in Table I. DNA ploidy and DI did not have
prognostic significance in the axillary nodes positive group,
whereas SPF was a significant prognostic factor in all patient
groups studied.
Correlations with other prognosticfactors
Correlation of DNA ploidy, DI and SPF with several
clinicopathological prognostic factors is shown in Tables II
and III. They show a strong correlation with many other
factors, such as histological type and grade, tubule forma-
tion, number of mitoses, nuclear pleomorphism, the primary
tumour size, extent of tumour necrosis, the presence of elas-
tin, axillary nodal status and the presence of distant meta-
stases at the time of the diagnosis.
Non-diploid DNA content was also associated with age at
diagnosis, 74% of the post-menopausal and 59% of the
premenopausal patients had non-diploid cancer (P = 0.004).
The mean age at diagnosis of the patients with a non-diploid
cancer was 56.2 years (s.d., 11.0 years), as compared with
53.9 years (s.d., 12.8 years) in patients with diploid cancer
(P = 0.03). The patients with tetraploid cancer were older
than those with aneuploid cancer at diagnosis (P = 0.006, the
mean age of the tetraploid group was 62.4 years, and that of
the aneuploid group 55.7 years), but the mean age of the
patients with multiploid cancer and those with aneuploid
cancer did not differ (P = 0.7).
DNA non-diploidy was associated with the clinical stage:
49%, 67%, 73% and 87% of the stage I, II, III and IV
tumours, respectively, were non-diploid (P = 0.01). Only 21
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Figure 2 Distribution of the DNA indices in 351 cases of breast
carcinoma. The DI of the diploid cancers is 1.00, of the near
diploid 1.05 and of the non-diploid >1.05.
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Figure 3 Survival corrected for intercurrent deaths by DNA
ploidy and DNA index. The number ofpatients at risk is given in
brackets. P values are given according to the Wilcoxon-Breslow/
Mantel-Cox tests.
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Figure 4 Corrected survival by the S-phase fraction (SPF). P
values are given according to the Wilcoxon-Breslow/Mantel-Cox
tests.
(17%) of the 123 patients with non-diploid cancer had SPF
<7% as compared with 72 (72%) of the diploid cancers
(P<0.0001). The median SPF of non-diploid tumours was
15.0% (mean 15.4%; S.D., 8.3%) as compared with 6.0%
(mean 6.8%; s.d., 3.5%) in diploid tumours (P = 0.0001).
No association of ploidy, DI or SPF could be found with
the extent of tumour stromal fibrosis, type of tumour margin,
presence of inflammatory carcinoma or skin ulceration,
mixed histology of the primary tumor, localisation of car-
1
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cinoma in the breast, laterality between the left and the right
breast, duration of symptoms, family history of breast cancer
or occurrence of a second primary cancer in other organs
during the follow-up. However, carcinomas with DI< 1.3
were more often associated with severe inflammatory cell
reaction than carcinomas with DI> 1.3 (P = 0.008), and also
non-diploid carcinomas had such a tendency (P = 0.08). Car-
cinomas with SPF <7% were more often associated with
principal intraductal growth pattern than those with SPF
>7% (P = 0.05).
Table I Influence of DNA ploidy, DNA index and S-phase fraction on 25-year corrected
survival when patients with breast cancer were stratified according to menopausal and axillary
nodal status
Premenopausal
Pw/Pm
Patient stratification
Post-menopausal No
Pw/Pm Pw/Pm
N, 3
P./P.
DNA ploidy 0.09/0.07 0.0006/0.001 0.008/0.01 0.28/0.35
diploid vs. n= 124 n= 225 n= 158 n= 191
non-diploid
DNA index 0.02/0.009 0.003/0.005 0.001/0.003 0.42/0.35
<1.30 vs. n= 124 n=225 n= 158 n= 191
>1.30
S-phase fraction 0.004/0.001 0.0001/0.001 0.01/0.02 0.0001/0.001
<7% vs. n = 78 n = 144 n = 104 n= 118
>7%
Significance of the difference in survival is given according to a Wilcoxon-Breslow test (Pw)
which givesgreater weight toearlyobservations, andaccording to a Mantel-Cox test(Pm), which
gives equal weight to all observations.
Table II Clinicopathological features in 351 cases ofbreast cancer and their relation to
DNA ploidy and the DN index (DI)
Feature n %
All patients
Age years
K49
>49
Histological type
ductal
lobular
tubular
medullary
other types
Histological grade
II
III
Tubule formation
extensive or
moderate
slight/none
Mitoses/HPFa
rare
2-3
>3
Nuclear pleo-
morphism
slight
moderate
severe
Necrosis
none
spotty
moderate
severe
Elastin
none
some to severe
Tumour size
T,(<2 cm)
T2(>2-5 cm)
T3(>5 cm)
T4
Nodal status
No
N1 3
Distant metastases
Mo
Ml
aHigh power field.
351
124 35
227 65
267
53
10
7
14
77
144
130
94
257
120
130
101
50
209
92
204
71
48
28
200
151
39
199
59
54
158
193
328
23
76
15
3
2
4
22
41
37
27
73
34
41
37
14
60
26
58
20
14
8
57
43
11
57
17
15
45
55
93
7
Non-diploid
240
73
167
201
23
4
6
6
26
104
110
49
191
56
96
88
8
157
75
123
55
38
24
148
92
20
134
43
43
93
147
220
20
% P
68
59 0.004
74
75 <0.0001
43
40
86
43
34 <0.0001
72
85
49 0.0001
74
47 <0.0001
74
87
16 <0.0001
75
82
60 0.001
77
79
86
74 0.009
61
51
67
73
80
59
76
67
87
0.03
0.0005
0.04
DI>1.30
202
57
145
177
13
1
6
5
15
85
102
% P
58
46 0.001
64
66 <0.0001
25
10
86
36
19 <0.0001
59
78
33 35 <0.0001
169 65
38 32 <0.0001
81 62
83 82
3
130
69
94
52
34
22
129
73
16
115
33
38
76
126
184
18
6 <0.0001
62
75
46 <0.0001
73
71
79
65 0.002
48
41 0.04
58
56
70
48 0.002
63
56 0.04
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Table III Clinicopathological features in 223 cases of breast cancer
and their relation to the S-phase fraction (cut-offpoint 7%)
Feature n %
All patients
Age years
<49
>49
Histological type
ductal
lobular
tubular
medullary
other types
Histological grade
I
II
III
Tubule formation
extensive or moderate
slight/none
Mitoses/HPFa
rare
2-3
>3
Nuclear pleomorphism
slight
moderate
severe
Necrosis
none
spotty
moderate
severe
Elastin
none
some to severe
Tumour size
T, (<2 cm)
T2 (>2-5 cm)
T3 (>5 cm)
T4
Nodal status
No
Distant metastases
Mo
Ml
aHigh power field.
223
78
145
165
39
S
2
12
58
103
62
74
149
87
85
51
41
141
41
138
42
29
14
124
99
24
127
38
34
104
119
204
19
35
65
74
17
2.5
1
5.5
26
46
28
33
67
39
38
23
18
64
18
62
19
12
7
56
44
11
57
17
15
47
53
91
9
SPF>7% %
130 59
38 49
92 63
113 68
11 28
0 0
2 100
4 33
12
68
50
31
99
28
60
42
5
92
33
67
30
22
11
81
49
9
73
24
24
52
78
112
18
21
66
81
42
66
32
71
82
12
65
80
49
71
76
79
65
49
38
57
63
71
50
66
55
95
p
0.03
<0.0001
<0.0001
0.0005
<0.0001
<0.0001
0.002
0.01
0.08
0.01
0.0008
Multivariate analyses
In order to find out the relative importance and inde-
pendence of DNA ploidy, DI and SPF as prognostic factors,
they were tested in Cox's proportional hazard model together
with all factors that had prognostic significance (P<0.05) as
a single factor in univariate analyses.
The results of univariate and Cox's multivariate analyses
are shown in Table IV. The most important independent
prognostic factor in a multivariate analysis was axillary nodal
status (No vs N1 3, P<0.001), followed by primary tumour
size (T, vs T2 vs T3 4, P<0.001), histological grade (grade I
vs grade II vs grade III, P<0.001), type of tumour margin
(definite vs diffuse, P<0.001), extent of tumour necrosis
(none to moderate vs severe, P = 0.01), and histological type
(other special types vs lobular vs ductal type, P = 0.02). DNA
ploidy and DI did not appear as independent prognostic
variables. However, if SPF was entered in the analysis, it had
independent prognostic value (P = 0.02). Furthermore, slight
nuclear pleomorphism, extensive or moderate tubule forma-
tion, low number of mitoses, extensive intraductal growth of
cancer and age <49 years at diagnosis had favourable
impact on prognosis in univariate analyses, but not in a
multivariate analysis.
If DNA ploidy, SPF and DI were tested together with the
other factors after stratifying the material according to the
axillary nodal status, the most important prognostic factor in
axillary node negative patients was primary tumour size
(P = 0.002), followed by type of tumour margin (P = 0.01)
and SPF (P = 0.02); and in axillary node positive patients
primary tumour size (P<0.001), histological grade
(P = 0.001), type of tumour margin (P = 0.02), extent of
tumour necrosis (P = 0.04) and SPF (P = 0.07). If the
material was stratified according to the menopausal status,
the most important prognostic factors in the premenopausal
group were axillary nodal status (P<0.001), type of tumour
margin (P = 0.01), mitotic count (P = 0.01), and tubule for-
mation (P = 0.03); and in the post-menopausal group axillary
nodal status (P<0.001), followed by histological grade
(P<0.001), primary tumour size (P<0.001) and type of
tumour margin (P = 0.02).
If crude survival was tested instead of corrected survival in
Cox's analysis (and age at diagnosis was excluded from the
tested variables), the relative significance of SPF, DI and
ploidy was somewhat greater. SPF (P<0.001) was the third
in rank after axillary nodal status (P<0.001) and primary
tumour size (P<0.001) in relative importance, and the most
important single factor (P = 0.002) in the axillary node698 S. TOIKKANEN et al.
Table IV Prognostic factors in breast cancer, and their influence on 25-year corrected
survival, results of univariate and multivariate analyses
Univariate analysis Multivariate analysis
All cases All cases Cases with evaluable
n = 349 n = 349 SPFn=222
Factor P x p Stepa P Stepa
Nodal status <0.0001 135.5 <0.001 1 <0.001 1
Tumour size <0.0001 120.5 <0.001 2 <0.001 2
Histological grade <0.0001 65.8 <0.001 3 <0.001 3
Tumour margin <0.0001 23.0 <0.001 4 <0.001 4
Tumour necrosis <0.0001 34.1 0.01 5 n.s.
Histological type <0.0001 34.7 0.02 6 n.s.
Nuclear pleomorphism <0.0001 35.5 0.08 7 n.s.
Menopausal status 0.02 5.1 0.09 8 n.s.
Mitotic count <0.0001 48.9 n.s. n.s.
Tubule formation <0.0001 25.5 n.s. n.s.
S-phase fractionb <0.0001 18.6 0.02 5
DNA indexc <0.0001 16.6 n.s. n.s.
DNA ploidy 0.0001 14.9 n.s. n.s.
Intraductal growth 0.02 5.5 n.s. n.s.
aStep of factor removal in Cox's multivariate stepwise analysis. bCut_off point 7%.
cCut-off point 1.30. n.s., statistically not significant.
negative group (n = 104). If both SPF and age were excluded
from the tested variables, DI with cut-off point 1.3
(P<0.001) became the most important variable predicting
crude survival in the axillary node negative group (n = 158).
Discussion
A non-diploid nuclear DNA content, DI value > 1.3 and
SPF> 7% were all correlated with adverse prognosis, and
the adverse effect was shown to last for 25 years after the
diagnosis. All these variables were associated with many of
the known prognostic factors in breast cancer, some of which
were more powerful prognostic factors than the ones derived
from the DNA content analysis in multivariate analyses.
To our knowledcge, there are no published studies in
which DNA content determination has been attempted from
paraffin embedded material that has been collected in the
1940 s and 1950 s. Although the number of uninterpretable
histograms was the greater the older the sample was (data
not shown), the majority of the histograms (89%) were of
acceptable quality. The histograms were classified without
knowledge of survival or clinicopathological data, and the
correlations found were stronger than in many series pro-
duced from more recent material (Dressler et al., 1988; Feich-
ter et al., 1988; Haag et al., 1984). The percentage of non-
diploid tumours found (68%) is almost identical to the mean
percentage of 67% found in 23 studies on breast cancer
comprising the total of 5,785 patients (data not shown).
Although DNA flow cytometry has been claimed to be an
objective method, the DNA histograms are not always
similarly interpreted, resulting in a different percentage of
DNA aneuplody found even if the data is similar (Joensuu &
Kallioniemi, 1989). The use of DI abolishes some of the
problems involved in data interpretation, since near diploid
tumours and tumours with a small DI may be grouped
together with the diploid tumours. DI is easy to calculate,
and was a slightly more powerful prognostic variable than
DNA ploidy (Table IV). The great majority of non-diploid
tumours have DI> 1.3 (Figure 2) and hence both DI> 1.3
and DNA non-diploidy are closely related variables (Figure
3).
The SPF value 7% was the most effective cut-off percen-
tage for prognosis. The value of SPF as a prognostic factor is
lessened by the fact that it often cannot be reliably assessed,
e.g. in cases with overlapping cell populations or presence of
cell debris. When SPF of diploid histograms is calculated, a
variable number of stromal and non-tumour cells are in-
cluded usually reducing the relative percentage of SPF,
whereas if SPF is calculated from an aneuploid stemline, only
cancer cells are considered, and SPF is likely to be higher. In
this series only 17% of non-diploid tumours had SPF <7%
as compared with 72% of the diploid tumours, which differ-
ence may partly be technical. Hence, SPF is also related to
DNA ploidy and DI.
Most authors agree that DNA aneuploidy is associated
with poor histological grade (Thorud et al., 1986; Moran et
al., 1984; Spyratos et al., 1987; Olszewski et al., 1981;
Jakobsen et al., 1984; Hedley et al., 1984; McDivitt et al.,
1986; Kute et al., 1985; Kallioniemi et al., 1987; Feichter et
al., 1988; Dowle et al., 1987), and the mitotic count, nuclear
pleomorphism and degree of tubule formation describe much
the same thing. The amount of elastin and the extent of
necrosis have been associated with histological grade too
(Fisher et al., 1984; Kuhajda et al., 1985). The association of
ploidy with primary tumour size and axillary nodal status
has been controversial (Uyterlinde et al., 1988; Spyratos et
al., 1987; Taylor et al., 1983; McDivitt et al., 1986; Cornelisse
et al., 1987; Dressler et al., 1988). In this series DNA aneu-
ploidy was significantly more common in large primary
tumours, and in tumours with axillary or distant metastases
(Table II). It has previously been largely unnoticed that the
type of tumour margin is an important prognostic factor in
both uni- and multivariate analyses, and this feature has
quite unexpectedly no correlation with the DNA analysis
derived factors.
The occurrence of aneuploidy in histological subtypes of
breast cancer has received scant attention; only mucinous
carcinomas have been extensively studied (Toikkanen et al.,
1988). The percentage of non-diploid tumours was high in
medullary (86%) and ductogenic NOS (74%) carcinomas,
and low in lobular (43%) and tubular (40%) carcinomas
(Table II). Survival of the patients with lobular carcinoma,
or with carcinoma of the other special types, was much better
than that of the patients with a ductogenic infiltrating NOS
carcinoma (P<0.0001). The medullary carcinoma, however,
was associated with a favourable outcome despite frequent
aneuploidy and, by definition, poor histological different-
iation. The good prognosis of medullary carcinoma appears
to depend on factors not associated with the ordinary favour-
able histological features, and it may be associated with its
definite circumscription and strong lymphocyte infiltration
(Hsu et al., 1981).
As in several other cancers (Joensuu et al., 1986; Klemi et
al., 1988), and even in benign tumours (Joensuu & Klemi,
1988), patients with a non-diploid breast tumour were older
than those with a diploid tumour (Table II). This has also
been noticed by Taylor et al. (1983). DNA aneuploid
tumours usually have hypertriploid DNA content, and it has
been suggested that DNA aneuploidy develops via tetra-DNA PLOIDY IN BREAST CANCER 699
ploidy: tetraploid tumours lose some of their chromosomal
material resulting in hypertriploid nuclear DNA content
(Ewers et al., 1984). However, patients with tetraploid cancer
were older at diagnosis than patients with aneuploid car-
cinoma (P = 0.006), which is poorly compatible with this
theory.
As expected, the ability of most of the factors listed in
Table IV to predict the final outcome decreased if crude
survival was studied instead of survival corrected for inter-
current deaths (P values became larger). However, the
opposite was true for age at diagnosis, and unexpectedly for
DI and SPF. Because special attention was paid to finding
the correct cause of death, deaths caused by breast cancer
misinterpreted as intercurrent deaths are not a likely explana-
tion for the stronger correlation of DI and SPF with crude
than with corrected survival. It is rather a further piece of
evidence for the association of advanced age and the
tendency to develop non-diploid solid tumours.
Most authors (Thorud et al., 1986; Coulson et al., 1984;
Hedley et al., 1987; Kallioniemi et al., 1987; Dowle et al.,
1987; Cornelisse et al., 1987; Ewers et al., 1984; Stal et al.,
1989), but not all (van der Linden et al., 1989; Uyterlinde et
al., 1988; Owainati et al., 1987), agree that DNA aneuploidy
is associated with unfavourable survival in breast cancer. In
most studies this association has, however, been weak. Cor-
nelisse et al. (1987) found only a slight correlation with
ploidy and overall survival (P = 0.04) despite having the
largest histologically verified material published so far
(n = 565). Contrary to our results, ploidy had no effect on
survival in the axillary node negative group, and it had an
independent impact on survival in the post-menopausal axil-
lary node positive group. Still others have found ploidy to be
significant in a univariate analysis, but not in a multivariate
analysis (Hedley et al., 1984; Stal et al., 1989). The most
promising results have been published by Kallioniemi et al.
(1987), who found DNA ploidy to be an independent prog-
nostic factor, even if survival was controlled for nodal status.
The results of different studies must be compared with
caution, since differences in histogram analysis, patient
materials, follow-up and statistical analyses may be con-
siderable. Unlike in most previous studies, the present series
comes from a defined well-documented population, and
includes all breast cancers in this area without any selection.
The number of clinicopathological factors studied exceeds
that of the previous works, which may have significance,
because the exclusion of any major prognostic factor from
the Cox's analysis may influence the result. However, steroid
receptor analyses were not available to us.
It is concluded that DNA ploidy, DI and SPF are impor-
tant prognostic factors in breast cancer, especially in axillary
node negative cancer and in post-menopausal patients, and
that they have long-term prognostic influence. However, they
are closely associated with other histological and clinical
prognostic factors related to cancer morphology, different-
iation, tumour size and spread. SPF could be shown to have
independent prognostic value in multivariate analyses, but
axillary nodal status, size of primary tumour, histological
grade and type of tumour margin were more powerful inde-
pendent prognostic factors. DNA ploidy and DI have prog-
nostic value as single variables in axillary node negative
patients, whereas SPF has such value both in axillary node
negative and positive patients.
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